Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, for Thromboprophylaxis After Total Hip Arthroplasty in Japan and Taiwan

被引：47

作者：

Fuji, T. ^{[1
]}

Wang, C. -J. ^{[2
]}

Fujita, S. ^{[3
]}

Kawai, Y. ^{[4
]}

Kimura, T. ^{[5
]}

Tachibana, S. ^{[6
]}

机构：

[1] Osaka Hosp, Dept Orthopaed Surg, Japan Community Hlth Care Org, Osaka, Japan

[2] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Orthoped Surg, Kaohsiung, Taiwan

[3] Takarazuka Daiichi Hosp, Dept Orthoped Surg, Takarazuka, Hyogo, Japan

[4] Int Univ Hlth & Welf, Tokyo, Japan

[5] Daiichi Sankyo Co Ltd, Clin Planning Dept, Tokyo, Japan

[6] Mishuku Hosp, Tokyo, Japan

来源：

JOURNAL OF ARTHROPLASTY | 2014年 / 29卷 / 12期

关键词：

edoxaban; factor Xa inhibitor; thromboembolic events; total hip arthroplasty; enoxaparin; TOTAL KNEE ARTHROPLASTY; VENOUS THROMBOEMBOLISM; REPLACEMENT; PREVENTION; WARFARIN;

D O I：

10.1016/j.arth.2014.05.029

中图分类号：

R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];

学科分类号：

摘要：

Edoxaban, an oral direct factor Xa inhibitor, has proven antithrombotic efficacy. In a multicenter, phase II study, 264 total hip arthroplasty (THA) patients randomly received edoxaban 15 or 30 mg once daily or enoxaparin 2000 IU (20-mg) twice daily for 11-14 days. Thromboembolic event incidences were 3.8% (3/78), 2.8% (2/72), and 4.1% (3/74) for edoxaban 15-mg, 30-mg, and enoxaparin, respectively (P = 1.00). Edoxaban-induced prolongation of prothrombin time, international normalized ratio, and activated partial thromboplastin time were proportional to plasma edoxaban concentration. Major or clinically relevant non-major bleeding incidences were 2.2% (2/89), 1.2% (1/85), and 2.3% (2/87) for edoxaban 15-mg, 30-mg, and enoxaparin, respectively (P = 1.00). Once-daily edoxaban showed similar efficacy and safety to enoxaparin for prevention of thromboembolic events in patients undergoing THA. (c) 2014 The Authors. Published by Elsevier Inc.

引用

页码：2439 / 2446

页数：8

共 15 条

[1] Pharmacology and management of the vitamin K antagonists [J].

Ansell, Jack ;

Hirsh, Jack ;

Hylek, Elaine ;

Jacobson, Alan ;

Crowther, Mark ;

Palareti, Gualtiero .

CHEST, 2008, 133 (06) :160S-198S

[2] Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism [J].

Bueller, Harry R. ;

Decousus, Herve ;

Grosso, Michael A. ;

Mercuri, Michele ;

Middeldorp, Saskia ;

Prins, Martin H. ;

Raskob, Gary E. ;

Schellong, Sebastian M. ;

Schwocho, Lee ;

Segers, Annelise ;

Shi, Minggao ;

Verhamme, Peter ;

Wells, Phil .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (15) :1406-1415

[3] A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement [J].

Eriksson, Bengt I. ;

Borris, Lars C. ;

Dahl, Ola E. ;

Haas, Sylvia ;

Huisman, Menno V. ;

Kakkar, Ajay K. ;

Muehlhofer, Eva ;

Dierig, Christoph ;

Misselwitz, Frank ;

Kalebo, Peter .

CIRCULATION, 2006, 114 (22) :2374-2381

[4] A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty [J].

Fuji, T. ;

Fujita, S. ;

Tachibana, S. ;

Kawai, Y. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (11) :2458-2468

[5] Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin [J].

Fuji, Takeshi ;

Ochi, Takahiro ;

Niwa, Shigeo ;

Fujita, Satoru .

JOURNAL OF ORTHOPAEDIC SCIENCE, 2008, 13 (05) :442-451

[6] Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients [J].

Fuji, Takeshi ;

Fujita, Satoru ;

Ochi, Takahiro .

INTERNATIONAL ORTHOPAEDICS, 2008, 32 (04) :443-451

[7]

Fujita S, 2000, CLIN ORTHOP RELAT R, P168

[8] DU-176b, a potent and orally active factor Xa inhibitor:: in vitro and in vivo pharmacological profiles [J].

Furugohri, T. ;

Isobe, K. ;

Honda, Y. ;

Kamisato-Matsumoto, C. ;

Sugiyama, N. ;

Nagahara, T. ;

Morishima, Y. ;

Shibano, T. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (09) :1542-1549

[9] Prevention of venous thromboembolism [J].

Geerts, William H. ;

Bergqvist, David ;

Pineo, Graham F. ;

Heit, John A. ;

Samama, Charles M. ;

Lassen, Michael R. ;

Colwell, Clifford W. .

CHEST, 2008, 133 (06) :381S-453S

[10] Edoxaban versus Warfarin in Patients with Atrial Fibrillation [J].

Giugliano, Robert P. ;

Ruff, Christian T. ;

Braunwald, Eugene ;

Murphy, Sabina A. ;

Wiviott, Stephen D. ;

Halperin, Jonathan L. ;

Waldo, Albert L. ;

Ezekowitz, Michael D. ;

Weitz, Jeffrey I. ;

Spinar, Jindrich ;

Ruzyllo, Witold ;

Ruda, Mikhail ;

Koretsune, Yukihiro ;

Betcher, Joshua ;

Shi, Minggao ;

Grip, Laura T. ;

Patel, Shirali P. ;

Patel, Indravadan ;

Hanyok, James J. ;

Mercuri, Michele ;

Vogelmann, O. ;

Gonzalez, C. ;

Ahuad Guerrero, R. ;

Rodriguez, M. ;

Albisu, J. ;

Rosales, E. ;

Allall, O. ;

Reguero, M. ;

Alvarez, C. ;

Garcia, M. ;

Ameriso, S. ;

Ameriso, P. ;

Amuchastegui, M. ;

Caceres, M. ;

Beloscar, J. ;

Petrucci, J. ;

Berli, M. ;

Budassi, N. ;

Valle, M. ;

Bustamante Labarta, G. ;

Saravia, M. ;

Caccavo, A. ;

Fracaro, V. ;

Cartasegna, L. ;

Novas, V. ;

Caruso, O. ;

Saa Zarandon, R. ;

Colombo, H. ;

Morandini, M. ;

Cuello, J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (22) :2093-2104

← 1 2 →